You are here

Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors

Read the full release


Gothenburg, Sweden, 2 June 2016 - Today, data from a post hoc analysis of the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the first European Obesity Summit (EOS 2016). 


Further information

Media:  
Katrine Sperling+45 4442 6718krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316kiau@novonordisk.com
   
Investors:  
Peter Hugreffe Ankersen+45 3075 9085phak@novonordisk.com
Melanie Raouzeos+45 3075 3479mrz@novonordisk.com
Kasper Veje (US)+1 609 235 8567kpvj@novonordisk.com

 

Attachment

Sunday, November 4, 2018 - 18:37